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Abstract
Age-related macular degeneration (AMD) is the most common reason of visual impairment in the elderly in the Western
countries. The degeneration of retinal pigment epithelial cells (RPE) causes secondarily adverse effects on neural retina
leading to visual loss. The aging characteristics of the RPE involve lysosomal accumulation of lipofuscin and extracellular
protein aggregates called ‘‘drusen’’. Molecular mechanisms behind protein aggregations are weakly understood. There is
intriguing evidence suggesting that protein SQSTM1/p62, together with autophagy, has a role in the pathology of different
degenerative diseases. It appears that SQSTM1/p62 is a connecting link between autophagy and proteasome mediated
proteolysis, and expressed strongly under the exposure to various oxidative stimuli and proteasomal inhibition. ELAVL1/HuR
protein is a post-transcriptional factor, which acts mainly as a positive regulator of gene expression by binding to specific
mRNAs whose corresponding proteins are fundamental for key cellular functions. We here show that, under proteasomal
inhibitor MG-132, ELAVL1/HuR is up-regulated at both mRNA and protein levels, and that this protein binds and post-
transcriptionally regulates SQSTM1/p62 mRNA in ARPE-19 cell line. Furthermore, we observed that proteasomal inhibition
caused accumulation of SQSTM1/p62 bound irreversibly to perinuclear protein aggregates. The addition of the AMPK
activator AICAR was pro-survival and promoted cleansing by autophagy of the former complex, but not of the ELAVL1/HuR
accumulation, indeed suggesting that SQSTM1/p62 is decreased through autophagy-mediated degradation, while ELAVL1/
HuR through the proteasomal pathway. Interestingly, when compared to human controls, AMD donor samples show strong
SQSTM1/p62 rather than ELAVL1/HuR accumulation in the drusen rich macular area suggesting impaired autophagy in the
pathology of AMD.
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Introduction
Age-related macular degeneration (AMD) is the most common
eye disease leading to visual impairment in the elderly in the
developed countries [1]. The disease affects the central retina
called the macula, the area that is responsible for the most
important sharp and colour vision [2]. AMD is associated with
aging, hereditary background, smoking, hypertension, hypercho-
lesterolemia, arteriosclerosis, obesity and unhealthy diet. In global
terms, 50 million people are affected by AMD with one third of
them suffering severe visual loss [3,4]. It is estimated that the
number of AMD patients will triple during the next decades due to
increased numbers of aged people [5].
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Primarily AMD is characterized by degeneration of the macular
retinal pigment epithelial (RPE) cells that secondarily leads to cell
death of photoreceptors (rods and cones) and visual loss [6]. AMD
has a progressive character and may develop into either a dry
(non-exudative) or wet (exudative) form [7,8]. Neovascularization,
sprouting from the choriocapillaris into the retina, is one of the
clinical hallmarks of wet AMD. The dry form of the disease is
more prevalent and it accounts for as many as 90% of all cases. At
present, no effective cure is available for dry AMD, although anti-
oxidants and omega-fatty acids have been shown to have
preventive properties in certain AMD patient groups [9,10]. In
wet AMD, monthly applications of intravitreal injections of anti-
VEGF antibodies have been used to suppress the activity of
neovascularization [11].
AMD pathogenesis involves chronic oxidative stress, increased
accumulation of lipofuscin in the lysosomes of RPE cells, as well as
extracellular drusen formation and presence of chronic inflam-
mation [2,12,13]. The ability to prevent the accumulation of
cytotoxic protein aggregates via autophagy may be decreased in
aged post mitotic RPE cells leading to degenerative changes.
Autophagy is basic catabolic mechanism which ’’self eats’’
cellular components that are unnecessary or dysfunctional to the
cell [14]. Autophagy comprises three intracellular pathways in
eukaryotic cells, which are macroautophagy (hereafter referred to
as autophagy), microautophagy and chaperone-mediated autoph-
agy [15]. Apart from its important role in cellular homeostasis,
autophagy is also triggered as an adaptive response during AMD-
associated stress conditions [2,6,14–17]. Autophagy process begins
with the formation of isolation membranes called phagophores;
these latter then become elongated and surround portions of
cytoplasm containing oligomeric protein complexes and organelles
to form mature double membrane autophagosomes. The autop-
hagosomes fuse with the lysosomes and their content is then
degraded by lysosomal enzymes. Failure of autophagy in aged
postmitotic cells, including RPE cells, can result in accumulation
of aggregate-prone proteins, cellular degeneration and finally cell
death [6].
SQSTM1/p62 (Sequestosome 1) is the best-characterized and
ubiquitously expressed autophagy receptor that connects protea-
somal clearance with lysosomes [18–22]. Alleviation of autophagy
is usually accompanied by an accumulation of SQSTM1/p62
mostly in large perinuclear aggregates or inclusion bodies which
are also positive for ubiquitin, as reported in numerous neurode-
generative diseases (such as Alzheimer’s disease, Parkinson’s
disease, and Huntington disease) [23–28].
The evidence indicates that SQSTM1/p62 is a stress response
gene strongly induced at mRNA and protein levels by the
exposure to various oxidative stimuli and proteasomal inhibitors
[29–32].
One of the most important post-transcriptional mechanisms
involves ELAVL1/HuR (embryonic lethal, abnormal vision,
Drosophila)-like 1 (Hu antigen R) protein, acting mainly as a
positive regulator of gene expression by binding to and increasing
the stability and/or translation of specific mRNAs whose
corresponding proteins are fundamental for key cellular functions.
It is noteworthy that ELAVL1/HuR, and in general ELAV
family, participates in various physio-pathological processes where
oxidation and stress play a primary role [33–35]. One of the main
aims of our study was to investigate whether SQSTM1/p62 mRNA
would be a target of ELAVL1/HuR protein, and whether the
binding between ELAVL1/HuR protein and SQSTM1/p62tran-
script exists in human RPE cells. We also investigated how
proteasomal and autophagy modulation affects SQSTM1/p62 and
ELAVL1/HuR expression. Moreover, their presence in drusen rich
human cadaver AMD samples was studied.
Materials and Methods
Ethics Statement
The study was approved by the Ethics Committee of the
Freiburg University Hospital, the University of Debrecen and the
tenets of the Declaration of Helsinki were followed for human
material. Participants provided their written informed consent for
the human material in this study.
Cell Culture and Treatments
ARPE-19 human RPE cells were obtained from the American
Type Culture Collection (ATCC). The cells were grown to
confluence in a humidified 10% CO2 atmosphere at 37uC in
Dulbecco’s MEM/Nut MIX F-12 (1:1) medium (Life Technolo-
gies, 21331) containing 10% inactivated fetal bovine serum
(Hyclone, SV30160-03), 100 units/ml penicillin and 100 mg/ml
streptomycin (Lonza, DE17-602E) and 2 mM L-glutamine
(Lonza, BE17-605E). In proteasome experiments, the cells were
exposed to 5 mM MG-132 proteasome inhibitor (Calbiochem,
474790) for 0,5 hours, 3 hours, 12 hours and 24 hours (h). The
cells were exposed to 50 nM bafilomycin A1 (Sigma, B1793) for
24 h. Additionally, the cells were treated with the AMPK (AMP-
activated protein kinase) activator, AICAR 2 mM (5-aminoimi-
dazole-4-carboxyamide ribonucleoside, Toronto Research Chem-
ical, A611700) for 0,5 h, 3 h, 12 h and 24 h. Furthermore, the
autophagy was induced with starvation by culturing cells in fetal
bovine serum free medium for 0,5 h, 3 h, 12 h and 24 h.
Cellular Fractionation and Western Blotting
The nuclear extract kit (40010) from Active motif was used for
the preparation of nuclear and cytoplasmic extracts from exposed
ARPE-19 cells. Proteins were collected according to the manu-
facturer’s protocol. The whole cell extracts were prepared in M-
PERH (Mammalian Protein Extraction Reagent, Thermo Scien-
tific, 78501) according to the manufacturer’s protocol.
Proteins were diluted in 2X sodium dodecyl sulphate (SDS)
protein gel loading solution, boiled for 5 minutes, separated on
12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
processed following standard procedures. The mouse monoclonal
antibodies were diluted as follows: the anti-ELAVL1/HuR (anti-
ELAVL/Hu) antibody (Santa Cruz Biotech, sc-5261) at 1:1000;
the anti-SQSTM1/p62 (anti-p62) antibody (Santa Cruz Biotech,
sc-28359) at 1:1000; the anti-MAP1LC3A/LC3 (anti-LC3,
microtubule-associated protein light chain 3A) antibody (Cell
Signaling, 3868) at 1:1000 and the anti-a-tubulin (Sigma, T9026)
at 1:1000. The nitrocellulose membranes signals were detected by
chemiluminescence. Experiments were performed in duplicate for
each different cell preparation and a-tubulin was used to
normalize the data. Statistical analysis of western blot data was
performed on the densitometric values obtained with the NIH
image software 1.61 (downloadable at http://rsb.info.nih.gov/nih-
image) and Quantity OneH software.
Fusion Plasmid Constructs
Human MAP1LC3A (LC3, light chain 3, NCBI gene bank no.
AF303888) was amplified from DNase-treated (DNase I, Roche,
04716728001) total RNA extracted (Eurozol reagent, Euroclone,
EMR055100) from human ARPE-19 cells. Initially, mRNA was
reverse-transcribed (MultiScribe reverse transcriptase, Applied
Biosystems, 4311235), and the MAP1LC3A/LC3 open reading
frame (ORF) was amplified with a high-fidelity DNA polymerase
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Figure 1. MG-132-induced increase of SQSTM1/p62 but not ELAVL1/HuR protein levels is counteracted by AICAR treatment.
Representative western blotting (upper) and densitometric analysis (lower) of SQSTM1/p62 (A), ELAVL1/HuR (B) and MAP1LC3A/LC3-II (C) proteins in the
total homogenates of ARPE-19 cells after starvation or/and exposure to AICAR (2 mM) or/and MG-132 (5 mM) for 0,5 h, 3 h, 12 h and 24 h. a-tubulin was
used as a loading control. Control cells were exposed only to solvent (DMSO). Results are expressed as means6 S.E.M. The data were analyzed by ANOVA,
followed by Dunnett’s Multiple Comparison Test; *p,0.05, **p,0.01, control vs. treated, n =7 (SQSTM1/p62 and ELAVL1/HuR), n = 3 (MAP1LC3A/LC3-II).
doi:10.1371/journal.pone.0069563.g001
Figure 2. SQSTM1/p62 transcript as a new target of the RNA-binding ELAVL1/HuR protein. (A): RNA-binding activity of ELAVL1/HuR
evaluated by AlphaScreen technology. Saturation binding experiments investigated by titrating a series of biotinylated single-stranded (BITEG-) RNAs,
including TNFneg and SQSTM1/p62neg, that we designated as negative controls, against 1 nM of rELAVL1/HuR. Calculated dissociation constants (Kd)
for TNFalpha (3.8360.69 nM, R2 = 0.97), and SQSTM1/p62 (30.85613.22 nM R2 = 0.91) are indicated. The plots represent mean 6 SD of two
independent experiments. (B): Saturation binding experiments as function of rELAVL1/HuR concentrations against four different type of RNA-
substrates at 50 nM concentration. 1 nM of rELAVL1/HuR was enough to reach saturation of the binding. The plots represent Mean 6 SD of two
independent experiments. (C): Effect of MG-132 exposure on SQSTM1/p62 gene expression. Determination of SQSTM1/p62mRNA by real-time qPCR in
human ARPE-19 cells following treatments with solvent (control) or 5 mM MG-132 for 24 hrs. SQSTM1/p62mRNA expression in control cells was taken
as 100%. The values obtained from total cellular mRNA have been normalized to the level of RPL6 mRNA and expressed as mean 6 S.E.M.
***p,0.001; Student’s t test; n = 3. (D): The binding of ELAVL1/HuR protein to SQSTM1/p62 transcript increases in the cytoplasm following MG-132
stimulus. Fold enrichment detected by quantitative real-time RT-PCR of SQSTM1/p62 mRNA in control and 24 h MG-132 RPE cells following
immunoprecipitation with anti-ELAV antibody (IP) in the cytoplasm. ***p,0.001, Student’s t-test, n = 3. The data of SQSTM1/p62 were normalized
with respect to the data obtained from immunoprecipitation with an irrelevant antibody as a negative control.
doi:10.1371/journal.pone.0069563.g002
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(Phusion Hot start DNA polymerase, Finnzymes, F-530S). The
following primers were used: sense 59-ATA CTCGAG at ATG
CCG TCG GAG AAG A and reverse 59-TGT AAG CTT g TTA
CAC TGA CAA TTT CAT CCC. The restriction sites for XhoI
and HindIII are in italics. The translation initiation and
termination sites are in boldface. The additional bases enabling
Figure 3. The MG-132-mediated upregulation of SQSTM1/p62 protein expression requires the specific presence of ELAVL1/HuR
protein. Representative western blotting (upper) and densitometric analysis (lower) of ELAVL1/HuR (A) and SQSTM1/p62 (B) proteins in the total
homogenates of ELAVL1/HuR silenced ARPE-19 cells and negative control (NEG-siRNA) cells after exposure to 5 mM MG-132 for 24 h. a-tubulin was
used as a loading control. Results are expressed as means 6 S.E.M. *p,0.05; **p,0.01; ***p,0.001, Tukey’s multiple comparison test; n = 5.
doi:10.1371/journal.pone.0069563.g003
Figure 4. Transmission electron micrographs of ARPE-19 cells exposed to AICAR or/and MG-132 and aggregate quantification. (A)
Representative transmission electron micrographs of ARPE-19 untreated control cells, cells exposed to AICAR 2 mM or/and MG-132 5 mM for 24 h.
Aggregates are indicated by arrows. (B) Quantification of aggregates in ARPE-19 cells exposed to AICAR 2 mM or/and MG-132 5 mM for 24 h. Eight
parallel samples were measured in all treatments. **p,0.01, Mann–Whitney.
doi:10.1371/journal.pone.0069563.g004
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in-frame cloning are in minuscules. The sticky ends for the
amplified MAP1LC3A/LC3 ORFs as well as for the multiple
cloning site of the vector pDendra2-C (Evrogen, FP821) were
produced with restriction endonucleases XhoI and Hind III (MBI
Fermentas, ER0691 and ER0501. respectively) [36]. Ligated (T4
DNA Ligase, Roche, 10481220001) DNA, forming a fusion gene
of Dendra2 and human MAP1LC3A/LC3 was transfected into
competent DH5a E. coli cells, which were prepared using the
protocol of Inoue and others and then cultured and purified
[37,38].The integrity of the construct, named hereafter as
pDendra2-hLC3 (MAP1LC3A/LC3), was determined initially
by restriction endonuclease digestion analysis and finally sequenc-
ing of both the junction sites and the entire inserted MAP1LC3A/
LC3 ORF.
Human Sequestosome 1, SQSTM1 (p62), NCBI gene bank no.
NM_003900) was similarly inserted into the pDendra2 vector. The
ORF insert was initially purchased from RZPD (Deutsches
Ressourcenzentrum fu¨r Genomforschung, IRAUp969A0698D).
The insert was amplified with the following primers: sense 59-ATA
CTC GAG at ATG GCG TCG CTC ACC; reverse 59-TAT AAG
CTT a TCA CAA CGG CGG GGG ATG. The restriction sites
for XhoI and HindIII are shown in italics and the translation
initiation and termination sites are in boldface. The additional
bases enabling in-frame cloning are in minuscules. The final
plasmid was named as pDendra2-hp62 (SQSTM1/p62).
Transfections and Confocal Imaging of pDendra2-hLC3
(MAP1LC3A/LC3) and pDendra2-hp62 (SQSTM1/p62)
ARPE-19 cells were cultured in 8-well plates (m-Slide, ibiTreat,
tissue culture treated, Ibidi, 80826) in a volume of 200 ml to a
subconfluent density. In all transfection experiments, ExGen
500 in vitro Transfection Reagent (MBI Fermentas, R0511) was
used and its protocol followed. The DNA content was 500 ng per
single well and the transfection treatment lasted for 24 h.
Chemical treatments with 5 mM MG-132 and/or 2 mM AICAR
followed for 24 h in fresh medium.
Before the microscopic evaluation, the medium was always
changed to a fresh medium without treatment. The nuclei were
stained with DRAG5TM (Biostatus, DR50050), diluted to 1/
1000 in phosphate-buffered saline. The fluorescent images were
obtained with a Zeiss Axio Observer inverted microscope (636NA
1,4 oil objective) equipped with Zeiss LSM 700 confocal module
(Carl Zeiss Microimaging). The change in the Dendra2 color from
green to red was achieved by treatment of the cells with 405 nm
UV-light [37].In the live cell imaging, a Zeiss XL-LSM S1
incubator with temperature and CO2 control was utilized. ZEN
2009 software (Carl Zeiss) was used for image processing.
Attenuation of the ELAVL1/HuR gene Expression by RNA
Interference
A control siRNA (NEG-siRNA) having no known homology
with any gene (Ambion, AM4641) and siRNA designed for the
human ELAVL1/HuR gene (Ambion, s4610) were used. The
ELAVL1/HuR siRNA has sense sequence GCG UUU AUC CGG
UUU GAC ATT, and the binding site is at the bases 615–633 of
the human ELAVL1/HuR gene (NCBI gene bank no.
NM_001419) in exon 2, near to the 59-end of the coding region.
siRNAs were transfected into ARPE-19 cells using siPORTTMA-
mine transfection reagent (Ambion, AM4502) following the
manufacturer’s instructions. Cells were grown as described above.
The concentration of siRNAs in cell cultures was 30 nM and
duration of siRNA treatment was held for 24 h, followed by MG-
132 treatment (5 mM) for 24 h. The decrease of ELAVL1/HuR
Figure 5. Transmission electron micrographs of ARPE-19 cells exposed to AICAR or/and MG-132 and autophagic vesicles
quantification. (A) Representative transmission electron micrographs of ARPE-19 cells exposed to MG-132 5 mM solely and with AICAR 2 mM for
3 h, 12 h and 24 h. Autophagic vesicles are indicated by arrows. (B) Quantification of autophagic vesicles in ARPE-19 exposed to MG-132 5 mM solely
and with AICAR 2 mM for 3 h, 12 h and 24 h. Six parallel samples were measured in all treatments. *p,0.05, **p,0.01, Mann–Whitney.
doi:10.1371/journal.pone.0069563.g005
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expression was monitored using real time quantitative RT-PCR
and western blotting.
Immunoprecipitation Followed by RNA Extraction
Immunoprecipitation on RPE cytoplasmic fractions was
performed according to a previously published protocol with
minor modifications [39]. Briefly, immunoprecipitation was
performed at room temperature for 2 h using 1 mg of anti-Hu
antibody per 50 mg of proteins diluted with an immunoprecipi-
tation buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM MgCl2,
0.05% Igepal, 20 mM EDTA, 100 mM DTT, protease inhibitor
cocktail and an RNAase inhibitor) in the presence of 50 ml of
protein A/G plus agarose (Santa Cruz Biotech, sc-2003). The
samples were finally subjected to RNA extraction. The negative
control was obtained under the same conditions, but in the
presence of an irrelevant antibody with the same isotype of the
specific immunoprecipitating antibody. One hundred microliters
of the immunoprecipitation mix were immediately collected from
each sample and used as ‘‘input signals’’ to normalize the RT-
PCR data.
Real-time Quantitative RT-PCR
RNA was extracted from total homogenates, immunoprecipi-
tated pellets and relative ‘‘input signals’’ by using RNeasy Micro
Plus Kit (Qiagen, 74034). The reverse transcription was performed
following standard procedures. PCR amplifications were carried
out using the Lightcycler instrument (Roche Molecular Biochem-
icals) in the presence of QuantiTect SYBR Green PCR mix
(Qiagen, 204143) with primers designed by using the PRIMER3
software (www-genome.wi.mit.edu/cgi-bin/primer/pri-
mer3_www.cgi). Primer sequences were as follows: ELAVL1/
HuR, 59-GAGGCTCCAGTCAAAAACCA -39 (upstream), 59-
GTTGGCGTCTTTGATCACCT -39 (downstrem); SQSTM1/
p62, 59- CTGGGACTGAGAAGGCTCAC -39 (upstream), 59-
GCAGCTGATGGTTTGGAAAT -39 (downstream); RPL6, 59-
AGATTACGGAGCAGCGCAAGATTG-39 (upstream), 59-
GCAAACACAGATCGCAGGTAGCCC-39 (downstream). The
RPL6 mRNA was chosen as the reference on which the ELAVL1/
HuR and SQSTM1/p62 values were normalized because it
remained relatively stable during all the treatments and it does not
bear adenine/uracil-rich elements (ARE) sequences (not shown).
In the statistical analysis the GraphPad Instat statistical package
(version 3.05 GraphPad software, San Diego) was used. The data
were subjected to analysis of variance (ANOVA) followed, when
significant, by an appropriate test, in function of the number of
samples. Differences were considered statistically significant when
p values ,0.05.
Figure 6. Colocalization of SQSTM1/p62 and MAP1LC3A/LC3 and position changes of SQSTM1/p62, revealed by confocal
microscopy analysis. A light merge orange/yellow signal of colocalizing MAP1LC3A/LC3 (pDendra2-hLC3, green) and SQSTM1/p62 (pDsRed2-
hp62, red) is detectable, usually near to the cell nuclei. Nuclei are stained with blue dye. The scale bar equals to 5 mm. (A): Confocal microscopy
images of untreated control ARPE-19 cells and cells exposed to AICAR 2 mM or/and MG-132 5 mM for 24 h. A =Aggregates (B): Position of SQSTM1/
p62 (pDendra2-hp62) in ARPE-19 cells, revealed by confocal microscopy analysis. SQSTM1/p62 in two different areas was photoconverted within
approximately 7 sec (circled). Within 1 minute after photoconversion, the photoconverted SQSTM1/p62 is stationary. Cells have been exposed to
5 mM MG-132 for 24 h. N =Cell nucleus.
doi:10.1371/journal.pone.0069563.g006
ELAVL1/HuR and SQSTM1/p62 Crosstalk in Autophagy
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e69563
Preparation of the Vector Expressing HuR cMyc-His-
tagged Protein
ELAVL1/HuR cDNA (NM 001419 ) was obtained and amplified
from MCF7-cells retro-transcribed RNA and inserted into the
pCMV6-AC-Myc-His PrecisionShuttle vector (PS100006; Ori-
gene Technologies) by using the forward (59- GCC GCGATCGC
CATGTCTAATGGTTATGA-39) and reverse (59-CGT
ACGCGT TTTGTGGGACTTGTTGG-39) primers containing
the SgfI and the MluI restriction sites (in italics), respectively. The
full-length open reading frame, with the Myc-His tag-encoding
sequence located at the 39-end, was confirmed by sequencing.
Recombinant vector pCMV6-HuR (ELAVL1/HuR) was trans-
fected (3 mg per 10 cm tissue culture dish) in HEK293T cells by
using LipofectamineH 2000 transfection reagent (Life Technolo-
gies, 11668019) according to the manufacturer’s protocol. Cells
were harvested 48 h after transfection and sonicated (3615
Figure 7. SQSTM1/p62 protein, but not ELAVL1/HuR protein, is degraded by autophagy in ARPE-19 cells. Representative western
blotting and densitometric analysis of SQSTM1/p62 (A) and ELAVL1/HuR (B) proteins in the total homogenates of ARPE-19 cells after exposure to
bafilomycin (50 nM) or/and MG-132 (5 mM) for 24 h. a-tubulin was used as a loading control. Results are expressed as means 6 S.D. The data were
analyzed by ANOVA, followed by Mann-Whitney; **p,0.01, untreated control cells vs. treated cells, n = 7.
doi:10.1371/journal.pone.0069563.g007
Figure 8. Sections of eyes with clinically diagnosed AMD immunostained for SQSTM1/p62. The extent of cytoplasmic immunopositivity
in the retinal pigment epithelial cells (RPE, shown by arrows) and in the drusen was evaluated microscopically (no staining or positive staining) by
selecting 5 mm long areas of foveomacular (A), perimacular (B) and peripheral (C) regions. The SQSTM1/p62 staining in the foveomacular areas was
more extensive as compared to the perimacular and peripheral areas (B and C, respectively). The drusen (shown by asterisks) were mostly SQSTM1/
p62 negative. The nuclei of RPE cells were SQSTM1/p62 negative. (Original magnifications of x 200 and in insets x 400; Bruch’s membrane shown by
arrow heads).
doi:10.1371/journal.pone.0069563.g008
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seconds, paused by 1 minute) with 75 of amplitude at 4uC, in
binding buffer (20 mM NaH2PO4, 0.5 M NaCl, 20 mM imidaz-
ole, pH 7.4) supplemented with Protease Inhibitor Cocktail
(Sigma, P8340). Recombinant ELAVL1/HuR HuR-Myc-His
proteins were purified by one-step affinity chromatography on
HisTrap HP columns (GE Healthcare, 17-5247-01) following the
recommended protocol and were eluted with 20 mM NaH2PO4,
0.5 M NaCl, 50 mM glycine, 300 mM imidazole, 10% glycerol,
pH 7.5.
Amplified Luminescent Proximity Homogenous Assay
Amplified Luminescent Proximity Homogenous Assay (AL-
PHA) was applied to study the interaction between recombinant
ELAVL1/HuR and two specific ARE-bearing RNA oligos designed
from 39UTRs of TNFalpha and SQSTM1/p62. Biotinylated single-
stranded TNFalpha [40] (59-AUUAUUUAUUAUUUAUUUA-
UUAUUUA-39), SQSTM1/p62 (59-GUUUUAAAUGACU-
CAUAGGUCCCUGACAUUUAGUUGAUU-39), TNFneg (59-
ACCACCCACCACCCACCCACCACCCA-39), SQSTM1/
p62neg (59-GCCCCAAACGACCCACAGGCCCCCGACACC-
CAGCCGACC-39) RNAs were purchased from Eurofins MWG
Operon and recombinant ELAVL1/HuR HuR-MYC/DDK
protein (TP301562) was purified from HEK293T cells transiently
transfected with pCMV6- ELAVL1/HuR. The assays were
performed in 384-well white OptiPlates (PerkinElmer, 6007299)
using a final volume of 25 ml and optimized by titrating both
interacting partners (in order to determine the optimal protein:
RNA ratio). Values out of the ‘‘hooking zone’’, where quenching
of the signal was due to an excess of the binding partner, were used
to determine the optimal concentrations of RNA-oligos and
proteins. All reagents were tested in the nanomolar range using the
Alpha Screen c-Myc detection kit (Perkin Elmer 6760611C) and
reacted in a buffer containing 25 mM HEPES (pH 7.4), 100 mM
NaCl, and 0.1% bovine serum albumin (BSA). Briefly, recombi-
nant ELAVL1/HuR protein (range 0.1–300 nM tested, data not
shown) was incubated with a biotinylated single-stranded RNA
(range 0.1–300 nM) and with anti-c-Myc Acceptor beads (20 mg/
ml final concentration) and, subsequently, the reaction was placed
Figure 9. Sections of eyes with clinically diagnosed AMD immunostained for ubiquitin. The extent of Bruch’s membrane
immunopositivity of the retinal pigment epithelial cells (RPE, shown by arrows) and in the drusen (asterisks) was evaluated microscopically (no
staining or positive staining) by selecting 5 mm long areas of foveomacular (A), perimacular (B) and peripheral (C) regions. The uniform staining of
ubiquitin in RPE cells Bruch’s membrane was observed in all these regions (arrows). There were no differences in the extent of staining between these
regions in each group. The nuclei of RPE cells were mostly ubiquitin negative. Most of the drusen were strongly ubiquitin-positive (asterisks). (Original
magnifications of x 200 and in insets x 400; Bruch’s membrane shown by arrow heads).
doi:10.1371/journal.pone.0069563.g009
Figure 10. Sections of eyes with clinically diagnosed AMD immunostained for ELAVL1/HuR. The immunopositivity of the nuclei of RPE
cells (shown by arrows) and the extent of immunopositivity in the drusen (asterisks) was evaluated microscopically (no staining or positive staining)
by selecting 5 mm long areas of foveomacular (A), perimacular (B) and peripheral (C) regions. The foveomacular nuclei showed less extensive
immunopositivity for ELAVL1/HuR than the perimacular and peripheral regions. However this difference was not statistically significant in any of the
groups studied (p.0.1). The cytoplasms of RPE cells were ELAVL1/HuR negative. Most of the drusen were ELAVL1/HuR-negative. (Original
magnifications of x 200 and in insets x 400; Bruch’s membrane shown by arrow heads).
doi:10.1371/journal.pone.0069563.g010
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in the dark at room temperature for 30 min. The incubation in the
same conditions was extended to 90 min after addition of
streptavidin Donor beads (20 mg/ml final concentration). Specific
interactions were quantified on a PerkinElmer Enspire plate
reader by subtracting the signal of the background (non-specific
binding). Dissociation constants (Kd) for TNFalpha (0.08760.021),
and SQSTM1/p62 (0.20760.024) were determined from nonlin-
ear regression fits of the data according to a 1-site binding model
in GraphPad PrismH, version 5.0 (GraphPad Software, Inc.).
Transmission Electron Microscopy
For transmission electron microscopy, the cells were treated
with 5 mM MG-132 and/or 2 mM AICAR for 3 h, 12 h and
24 h. Cell culture samples were prefixed with 2.5% glutaraldehyde
in 0.1 M phosphate buffer pH 7.4 for 2 h at RT. After 15 min
washing in 0.1 M phosphate buffer, the samples were post-fixed in
1% osmium tetraoxide and 0.1 M phosphate buffer for 1 hour,
and again washed with phosphate buffer for 15 min prior to
standard ethanol dehydration. Subsequently, the samples were
infiltrated and embedded in LX-112 resin. Polymerization was
carried out at 37uC for 24 h and at 60uC for 48 h. The sections
were examined with a JEM-2100F transmission electron micro-
scope (Jeol) at 200 kV.
Aggregates and autophagic vesicles were manually counted.
Eight cells were randomly selected from each group for counting
aggregates and six cells for autophagic vesicles. Statistical analysis
was performed using SPSS (v. 19; IBM, SPSS Inc). The
significance of differences between control and treated groups
was analyzed with Mann-Whitney U-test. p-values ,0.05 were
considered significant.
Cytotoxicity Assay
Cytotoxicity to the AICAR and other treatments was monitored
by measuring the amount of lactate dehydrogenase (LDH) enzyme
from the culture medium samples. The Cyto-Tox 96 Non-
Radioactive Cytotoxicity Assay kit (Promega, G1781) was used
for detection according to the instructions of the manufacturer.
Absorbance values after the colorimetric reaction were measured
at a wavelength of 490 nm with a reference wavelength of 655 nm
using a BIO-RAD Model 550 microplate reader. Statistical
analysis was performed using SPSS program (v. 19; IBM SPSS
Inc). The significance of differences between control and treated
groups was analyzed with Mann-Whitney U-test (n = 6). p-values
,0.05 were considered significant.
Assay for Cell Death Analysis
Cell death was assessed by the Annexin-V-fluorescein isothio-
cyanate. We used the Apoptosis Detection Kit (MBL, BV-K 101-
4) according to the manufacturer’s recommendations; the propor-
tion of stained Annexin-V+ and Annexin-V+/Propidium iodide+
cells was determined by fluorescence activated cell sorter (FACS)
analysis on FACS Calibur flow cytometer (BD Biosciences
Immunocytometry Systems, San Jose, CA, USA) and data were
analyzed using WinMDI freeware (Joseph Trotter, La Jolla).
Immunohistochemistry
Patients with dry AMD rich with drusen had been diagnosed
based on biomicroscopy and fundus photographs in the Depart-
ment of Ophthalmology of Freiburg University Hospital. The
study was approved by the Ethics Committee of the Freiburg
University Hospital and the tenets of the Declaration of Helsinki
were followed. Eyes from two age-matched patients without
clinically diagnosed AMD were used as a control; one eye was
provided by the Department of Ophthalmology of Freiburg
University Hospital and the other one by the Department of
Ophthalmology of University of Debrecen. In both cases, the
tenets of the Declaration of Helsinki were followed. Enucleated
eyes from cadaver human samples were embedded in paraffin
according to a routine protocol and horizontal sections (5 mm) of
four eyes were immunostained for SQSTM1/p62, ubiquitin (Ub)
and ELAVL1/HuR. The extent of immunopositivity in the retinal
pigment epithelial cells was evaluated microscopically (no staining
or positive staining) by selecting 5 mm long areas of the
foveomacular, perimacular and peripheral regions. All the
horizontal sections were, based to the histological anatomy, from
the corneal level. Foveomacular, perimacular and peripheric areas
Figure 11. Sections of foveomacular areas of age-matched control eyes for SQSTM1/p62, ubiquitin and ELAVL1/HuR. The extent of
cytoplasmic immunopositivity for SQSTM1/p62, Bruch’s membrane immunopositivity for ubiquitin and the immunopositivity of nuclei of RPE cells for
ELAVL1/HuR (foveomacular areas shown; A, B and C respectively) in the RPE cells (shown by arrows) was evaluated microscopically (no staining or
positive staining). For SQSTM1/p62 there were only a few immunopositive cytoplasm’s randomly distributed through-out the RPE cell layer and the
nuclei were negative. Bruch’s membrane (shown by arrowheads) was immunopositive for ubiquitin occasionally through-out the RPE cell layer in very
small amounts while all of the nuclei were negative. Half of the nuclei showed minor immunopositivity for ELAVL1/HuR while the cytoplasm’s of RPE
cells were negative. The foveomacular areas showed no difference in immunohistochemical stainings when compared to areas of perimacular and
peripheral retina in all of the proteins studied. (Original magnifications of x 200 and in insets x 400).
doi:10.1371/journal.pone.0069563.g011
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were analysed as a pack from the same horizontal section. The
stainings were done with Thermo Scientific’s UltraVision LP
Detection System AP Polymer & Fast Red Chromogen (TL-015-
AF) kit according to the manufacturer’s instructions. The
antibodies used were mouse monoclonal for SQSTM1/p62 (Santa
Cruz, sc-28359), rabbit polyclonal for ubiquitin (Dako, Z0458) and
the mouse monoclonal for ELAVL1/HuR (Santa Cruz, sc-5261).
The dilutions were 1:500, 1:1100 and 1:500 respectively. Human
brain with Alzheimer’s disease was used as a method control for
the stainings (data not shown). After the staining samples were
analyzed as described above, using a Zeiss AX10 Imager A2
(Go¨ttingen) light microscope and a Jenoptik ProgRes C5 (Optical
Systems) digital camera mounted on to the microscope. Photo-
graphs were taken with the same camera. The statistical analysis
for the results was conducted with a Mann-Whitney test in the
SPSS Statistics 17.0 program (IBM SPSS Inc).
Results
AICAR Treatment Strongly Counteracts the MG-132-
induced Increase of SQSTM1/p62 Protein Levels in ARPE-
19 Cells
In order to identify the optimal conditions to study the effects on
SQSTM1/p62 protein levels, the ARPE-19 cells were first treated
with the proteasome inhibitor MG-132 (5 mM) and/or the
autophagy activator, AICAR (2 mM) over a time range (data
not shown). Western blotting analysis revealed that a statistically
significant change in total SQSTM1/p62 protein levels was
detectable only after 24 h treatments, so this time point was
selected for further studies. In particular, as shown in Figure 1A,
the proteasome inhibitor MG-132 significantly increased total
SQSTM1/p62 protein levels, while concomitant treatment with
MG-132 and AICAR robustly decreased SQSTM1/p62 protein
levels. In contrast, no difference in SQSTM1/p62 protein levels
was detected after exposure to AICAR alone (Fig. 1A). Interest-
ingly, by performing cellular fractionation, we found that in
comparison to control cells, MG-132 evoked a significant increase
in the SQSTM1/p62 protein levels mainly in the nuclear/
perinuclear compartment and also in the cytoplasm (+1658%,
p,0.05 and +48%, p,0.001, respectively; Fig. S1A). Analogously
to SQSTM1/p62, MG-132 also significantly increased ELAVL1/
HuR protein levels in the nuclear/perinuclear compartment, in
the cytoplasm (+154%, p,0.001 and +64%, p,0.01 respectively;
Fig. S1B) and in the total homogenate (Fig. 1B). In contrast to
SQSTM1/p62, the MG-132-induced increase of ELAVL1/HuR
protein was not affected by the concomitant treatment with
AICAR, as reported in Figure 1B, suggesting that ELAVL1/HuR
protein is not degraded via autophagy.
To confirm the capability of AICAR to induce autophagy,
MAP1LC3A/LC3–II protein levels were detected after 0,5 h, 3 h,
12 h and 24 h by western blotting (Fig. 1C). Indeed, when co-
treated with MG-132, AICAR clearly increased MAP1LC3A/
LC3-II protein levels after 0,5 h, while after 24 h treatment
MAP1LC3A/LC3 lipidation was already over (Fig. 1C), in
accordance with the SQSTM1/p62 levels. We also wanted to
compare AICAR response with starvation, a condition that is
known as autophagy inducer. As well as for AICAR, starvation-
induced autophagy required the presence of the proteasome
inhibitor MG-132; conversely to AICAR, starvation-induced
autophagy under proteasome inhibition begun later than AICAR
(3 h vs 0,5 h) in ARPE-19 cells.
Table 1. Cytoplasmic SQSTM1/p62, ubiquitin and ELAVL1/
HuR proteins in foveomacular, perimacular and peripheral RPE
cells.
SQSTM1/p62 Macula Perimacula Peripheral retina
Sample Percentage (%) Percentage (%) Percentage (%)
1 100 48 0
2 100 64 0
3 92 16 12
4 100 26 36
5 90 7 36
6 100 48 0
7 100 38 24
8 100 22 18
MA; SD (%) 97,8; 4,2 33,6; 19,2 15,8; 15,4
Ubiquitin Macula Perimacula Peripheral retina
Sample Percentage (%) Percentage (%) Percentage (%)
1 15 30 0
2 14 44 9,6
3 64 66 40
4 70 56 26
5 70 26 32
6 64 32 30
7 20 9 7,4
8 16,4 16,8 4
MA; SD (%) 41,7; 27,2 35,0; 19,3 18,6; 15,1
ELAVL1/HuR Macula Perimacula Peripheral retina
Sample Percentage (%) Percentage (%) Percentage (%)
1 6,7 8,7 0
2 32,6 0 66,7
3 56,4 100 61,5
4 5,6 36,4 56,2
5 30,4 50 42,5
6 38,3 35,4 27,1
7 0 0 0
8 0 0 0
MA; SD (%) 21,3; 21,1 28,8; 34,9 31,8; 28,9
P-value for SQSTM1/p62 between macular-perimacular and macular-peripheral
retina groups is p,0.001. The differences among the three groups for ubiquitin
and ELAVL1/HuR are not statistically significant (p.0.1, Mann-Whitney test).
Eight 5 mm long regions from macular, perimacular and peripheral retina were
selected from eyes with clinically diagnosed AMD. If the optical nerve was
visible, the macular area was selected next to it; if not, a region which contained
most drusen was selected. Peripheral regions were selected close to the ora
serrata so that it would have as few as possible drusen. The perimacular region
was selected between these two so that it would contain few drusen. The
extent of cytoplasmic immunopositivity was measured and its percentage in
relation to the whole measurement was calculated. The statistical analysis for
the results was conducted with a Mann-Whitney test. MA=mean value,
SD= standard deviation.
doi:10.1371/journal.pone.0069563.t001
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MG-132 Treatment Triggers the Up-regulation of
SQSTM1/p62 Expression through the RNA-binding
ELAVL1/HuR Protein
It has been documented that SQSTM1/p62 is oxidative stress-
related and ubiquitin-binding protein [40]. We here confirmed
that 24 h MG-132 treatment induces the increase of SQSTM1/p62
mRNA expression in the total homogenate of ARPE-19 cells (Fig.
S2B). Then we wanted to determine whether a positive regulation
of SQSTM1/p62 expression occurs also at post-transcriptional level
in human ARPE-19 cells, following MG-132 treatment.
First, we analyzed the SQSTM1/p62 sequence to identify the cis-
acting elements and the corresponding trans-acting factors
potentially affecting SQSTM1/p62 mRNA stability and/or trans-
lation. A detailed primary sequence analysis of SQSTM1/p62
revealed the presence of ARE in the 39-untranslated region (39-
UTR), three of which (AUUUA) represent the canonical class I
sequence recognized by the RNA-binding ELAV proteins. This
region was consequently selected to design a probe used in protein-
RNA binding AlphaScreen assay, an in vitro technology which can
be utilized to evaluate the possible binding between ELAVL1/
HuR protein and SQSTM1/p62 mRNA. An ARE-bearing probe,
a portion of TNFa 39UTR, was employed as the positive control
of the experiment since it contains well characterized ELAV-target
sequences [41]. As shown in Figure 2A and 2B, ELAVL1/HuR
protein physically interacts with the SQSTM1/p62 probe, leading
to the formation of a stable protein-RNA probe complex. From
saturation binding experiments we calculated the dissociation
constants for the two RNA probes. The resulting binding
efficiency for the SQSTM1/p62 probe was 8 times weaker than
the TNFa probe, as it can be reasonably explained by the presence
of four canonical AREs within the TNFa probe compared to the
one present in the SQSTM1/p62 probe.
To confirm the finding obtained in the in vitro experiments and
to evaluate whether the binding between ELAVL1/HuR protein
and SQSTM1/p62 mRNA exists also in our cell system, we then
performed immunoprecipitation coupled with RT-real-time
qPCR experiments on control and MG-132 treated cells. It was
found that the MG-132-induced up-regulation of SQSTM1/p62
mRNA in the cytoplasm of ARPE-19 cells (Fig. 2C) was
accompanied by a parallel increase of the binding between
ELAVL1/HuR protein and SQSTM1/p62 mRNA in the same
cellular fraction (Fig. 2D), indicating that MG-132 treatment
induced a positive regulation of SQSTM1/p62 expression that
occurred also at post-transcriptional level via ELAVL1/HuR
protein. To further confirm this hypothesis, we silenced ELAVL1/
HuR expression in ARPE-19 cells by siRNA technology and then
exposed these cells to MG-132 for 24 h. First, we found that MG-
132 treatment strongly up-regulates ELAVL1/HuR mRNA ex-
pression in ARPE-19 cells (Fig. S2A). Conversely, in silenced cells,
MG-132 does not affect ELAVL1/HuR mRNA total amount, that
is indeed comparable to control levels (Fig. S2A). We then
evaluated ELAVL1/HuR protein levels finding that, besides
ELAVL1/HuR mRNA, ELAVL1/HuR-siRNA also counteracted
MG-132-induced ELAVL1/HuR protein accumulation
(Figure 3A). In parallel, we found that, in ELAVL1/HuR-silenced
cells, the MG-132 exposure leads to an up-regulation of SQSTM1/
p62 mRNA expression in a less extent than in MG-132-treated
control cells (Fig. S2B). Moreover, the MG-132-induced increase
of SQSTM1/p62 protein was counteracted in ELAVL1/HuR
silenced cells (Fig. 3B), for the first time suggesting that the positive
regulation of SQSTM1/p62 expression, during proteasomal
inhibition, requires the specific presence of ELAVL1/HuR
protein.
AICAR Promotes the Complete Clearance of MG-132-
induced Protein Aggregates, SQSTM1/MAP1LC3A (p62/
LC3) Co-localization and Autophagy-related Gene
Expression
As shown in Figure 1A, SQSTM1/p62 protein levels decreased
following concomitant treatment with MG-132 and AICAR,
subsequently we investigated in more detail the capacity of
AICAR to affect protein aggregation which normally occurs under
proteasome inhibition in ARPE-19 cells. The cells were thus
exposed to AICAR and MG-132 and protein aggregates were
examined in a transmission electron microscope. As shown in
Figure 4, AICAR was able to completely abolish the MG-132-
induced protein aggregation after 24 h treatment. Moreover, there
was also observed obvious reduction of aggregates after 3 h and
12 h AICAR- and MG-132-co-treated cells (data not shown).
Consistently with Figure 1 results, the amount of autophagic
vesicles increased during first 3 and 12 hours significantly when
cells were treated with AICAR together with MG-132 (Fig. 5).
These results show that this concomitant treatment strongly
switches-on autophagy at early time and clearance is already over
after one day.
Figure 12. Summary of the results. The proteasome inhibitor MG-
132 down-regulates (2) the ubiquitin-proteasome pathway (UPP).
AMPK-activator AICAR and proteasome inhibitor MG-132 co-treatment
activates (+) the autophagy. UPP inhibition significantly increases (+)
SQSTM1/p62 protein levels, while autophagy induction during UPP
inhibition robustly decreases (2) SQSTM1/p62 protein levels. Since
SQSTM1/p62 localizes to aggregates, the decreasing of SQSTM1/p62
reveals its autophagy clearance. In addition, proteasome inhibition
significantly increases ELAVL1/HuR protein levels by itself and during
the autophagy induction (+). Proteasome inhibition induces a positive
regulation of SQSTM1/p62 expression that occurs also at post-
transcriptional level via ELAVL1/HuR protein (+). Activated autophagy
is able to completely abolish the MG-132-induced protein aggregation
(2), which, in turn improves the cell vitality. Ubiquitin is also found in
intracellular aggregates in ARPE-19 cells as well as from drusens. In
contrast, SQSTM1/p62 is found only in the intracellular aggregates in
ARPE-19 cells, but not in drusens. However, SQSTM1/p62 levels were
high in macular area of RPE cells revealing impaired autophagy. What is
the relation between drusen and intracellular aggregates remains still
unknown. Red lines with minus symbol represent inhibiting and
decreasing events in ARPE-19 cells. Black lines and plus symbol
represent activating and increasing events in the ARPE-19 cell. Zero (0)
and dark blue line indicate neutral effects in the ARPE-19 cell. UPP:
ubiquitin-proteasome pathway.
doi:10.1371/journal.pone.0069563.g012
ELAVL1/HuR and SQSTM1/p62 Crosstalk in Autophagy
PLOS ONE | www.plosone.org 12 July 2013 | Volume 8 | Issue 7 | e69563
Since it is known that SQSTM1/p62 protein contains
MAP1LC3A/LC3 interacting domain [42] we evaluated if
SQSTM1/p62 protein would be co-localized with the autophago-
some marker MAP1LC3A/LC3 under different stimuli in ARPE-
19 cells. The cells were transfected with pDendra2-hLC3
(MAP1LC3A/LC3) and pDsRed2-hp62 (SQSTM1/p62) plas-
mids, exposed to AICAR and MG-132 as previously described in
the text, and analyzed by live confocal microscopy. Figure 6A
illustrates that MAP1LC3A/LC3 and SQSTM1/p62 proteins co-
localized after all treatments and that a clear perinuclear
accumulation of both proteins could be seen after MG-132-
induced proteasome inhibition. In agreement with previous data,
the cells treated concomitantly with MG-132 and AICAR
exhibited a strong reduction of the perinuclear aggregates
containing both MAP1LC3A/LC3 and SQSTM1/p62 proteins
(Fig. 6A). In addition, we noted that MAP1LC3A/LC3 punctas
were somewhat larger in AICAR-treated cells than untreated cells.
This interesting observation remains still to be studied.
Accumulated SQSTM1/p62 Protein is Stationary
Following 24 hours’ Proteasome Inhibition in ARPE-19
Cells
It has been previously shown that SQSTM1/p62 protein
accumulates in perinuclear aggregates that undergo autophagy
clearance [18,21]. According to our unpublished data there are
proteins that have reversible binding capacity to perinuclear
aggregates. Therefore, we wanted to evaluate whether binding of
SQSTM1/p62 to aggregates is reversible or irreversible prior to
autophagy.
In order to observe whether, under MG-132 stimulus, the
increased SQSTM1/p62 protein levels were accompanied by its
intracellular translocation in ARPE-19 cells, the fusion protein
plasmid construct pDendra2-hp62 (SQSTM1/p62) was created
and transfected to cells. Confocal microscopy was used for live cell
imaging and the movement of SQSTM1/p62 protein was
evaluated after photo converting pDendra2-hp62 (SQSTM1/
p62) (Fig. 6B). Two areas containing SQSTM1/p62 protein were
photoconverted: the intensively aggregated SQSTM1/p62 and
the amorphously aggregated SQSTM1/p62. We detected no
position changes of SQSTM1/p62 protein from the converted
area to other parts of the cell within 1 minute, indicating that
accumulated SQSTM1/p62 is stationary in ARPE-19 cells treated
for 24 h.
AICAR is Well-tolerated and Prevents Cell Death in MG-
132 Long-exposed ARPE-19 Cells
Next we evaluated how well ARPE-19 cells could tolerate
exposure to AICAR. Cellular toxicity was evaluated in two ways
after 24 h exposure to AICAR on its own and/or with the
proteasome inhibitor MG-132 by lactate dehydrogenase and
Annexin-V assays. AICAR treatment, in the presence or absence
of the proteasome inhibitor, did not increase lactate dehydroge-
nase release as compared to untreated control cells after 24 h (Fig.
S3A), evidence of the good cellular tolerability towards AICAR.
Annexin-V and Propidium Iodide double staining revealed that
MG-132 treatment is able to induce apoptosis after prolonged (48
and 72 h) exposure; in particular, we found that proteasome
inhibition clearly induced early and late apoptosis, the latter being
more pronounced after 72 h of treatments (Fig. S3B). After
exposure for both 48 and 72 h to MG-132, the concomitant
presence of AICAR counteracted the apoptotic effects, indicating
that AICAR exerted cytoprotective properties against proteasome
inhibition in ARPE-19 cells, by favoring autophagy which reduced
proteasome blockade-induced toxicity.
SQSTM1/p62 Protein, but not ELAVL1/HuR Protein, is
Degraded by Autophagy
Bafilomycin is known to be an autophagy inhibitor preventing
the fusion of autophagosomes and lysosomes, although effect may
change between cell types and exposure time [43]. To test how
bafilomycin affects SQSTM1/p62 protein expression in ARPE-
19, these cells were treated with either 50 nM bafilomycin or
5 mM MG-132 or with both agents simultaneously, and total
protein extracts were analyzed by western blotting. In accordance
with our previous experiments, ARPE-19 cells treated with
bafilomycin displayed a dramatic increase of SQSTM1/p62
protein levels (Fig. 7A). In addition, when cells were exposed to
both bafilomycin and MG-132, there was a statistically significant
increase of SQSTM1/p62 protein amount compared to untreated
(Fig. 7A), although to a lesser extent than with bafilomycin alone,
implying that SQSTM1/p62 clearance was mediated via autoph-
agy in ARPE-19 cells. Conversely, we did not observe any change
in ELAVL1/HuR protein levels after bafilomycin (Fig. 7B),
further indicating that ELAVL1/HuR protein was being degraded
via proteasome.
SQSTM1/p62 Protein Levels in the Foveo-macula Areas of
AMD Patients
Since, it is uncertain that the compounds used to regulate
autophagy in the cell culture model also mimic cellular aging and
age-related disease we wanted to analyze these key proteins in
human tissue samples. The SQSTM1/p62 staining in the
foveomacular areas of the AMD patients was more extensive
compared to the perimacular and peripheral areas (p,0.001), the
latter representing the internal control (Fig. 8; Table 1). The
drusen were mostly SQSTM1/p62 negative while the nuclei of
RPE cells were SQSTM1/p62 negative. A uniform staining of
ubiquitin in RPE cells and Bruch’s membrane was observed in all
these regions (Fig. 9). There were no differences in the extent of
ubiquitin staining between these regions in all groups (p.0.1)
(Table 1). Most of the nuclei of RPE cells were ubiquitin negative
and most of the drusen were strongly ubiquitin positive. The
foveomacular nuclei showed less extensive immunopositivity for
ELAVL1/HuR protein than the perimacular and peripheral
regions (Fig. 10). However this difference was not statistically
significant in any of the groups studied (p.0.1) (Table 1). The
cytoplasms of RPE cells were ELAVL1/HuR negative while the
drusen were mostly ELAVL1/HuR negative. We also performed
the same immunohistochemistry experiments in age-matched
control samples. We found that they were mostly SQSTM1/p62
negative, especially in the macular region (Fig. 11A); all of the
nuclei of RPE cells were negative, and there were only a few
SQSTM1/p62 immunopositive cytoplasms randomly distributed
through-out the RPE cell layer. In the control patient samples
Bruch’s membrane was mostly immunonegative for ubiquitin;
occasionally through-out the RPE cell layer, few cytoplasms were
weakly ubiquitin positive, while all of the nuclei were negative in
all the regions studied (Fig. 11B). In these control sections, half of
the nuclei showed weak immunopositivity for ELAVL1/HuR
while the cytoplasms of RPE cells were negative through-out the
RPE cell layer (Fig. 11C).
Discussion
In this study, we show for the first time that in ARPE-19 cells
proteasome inhibition leads to increased ELAVL1/HuR expression
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by acting in a dual manner: on one side inducing ELAVL1/HuR
transcription and, on the other side, decreasing its protein
degradation; during proteasomal inhibition ELAVL1/HuR pro-
tein binds to SQSTM1/p62 mRNA to potentiate post-transcrip-
tionally SQSTM1/p62 expression levels in ARPE-19 cells.
SQSTM1/p62 protein is cleansed by autophagy after its
stationary binding to perinuclear protein aggregates during
proteasome inhibition. The cleansing can be accelerated by
exposure to the AMPK activator AICAR, which counteracts the
MG-132 -mediated damaging effects and improves survival in
RPE. Interestingly, SQSTM1/p62 rather than ELAVL1/HuR
protein accumulates strongly in the drusen rich macular area in
human cadaver dry AMD samples - an evidence for impaired
autophagy in the pathology of AMD. These major findings are
schematically summarized in Figure 12.
Many previous studies have focused on to the transcriptional-
dependent events that affect SQSTM1/p62 expression, whereas
little data is available on SQSTM1/p62 post-transcriptional
control. Our findings indicate that, in response to MG-132
stimulus, the elevation in SQSTM1/p62 mRNA levels is due to the
activation of specific intracellular molecular cascades that are not
simply at the transcriptional level, but also involve the downstream
fate of SQSTM1/p62 transcript through the RNA-binding
ELAVL1/HuR protein. Indeed, we first identified within
SQSTM1/p62 39-UTR primary sequence the presence of ARE,
that are putative ELAV-binding sites. The in vitro experiment
seems to confirm our prediction, demonstrating that the recom-
binant HuR protein binds specifically to the ARE-bearing RNA
probe of SQSTM1/p62. The ELAVL1/HuR protein capability to
bind to SQSTM1/p62 mRNA was further validated in vitro by
immunoprecipitation and real time qPCR experiments. In
particular, the isolation of the transcripts co-immunoprecipitated
with endogenous ELAVL1/HuR protein showed that this RNA
binding protein had associated with SQSTM1/p62 mRNA more
prominently after proteasome inhibition in ARPE-19 cells.
Proteasome inhibition caused ELAVL1/HuR protein accumula-
tion, an increase in the amount of SQSTM1/p62 protein and
mRNA and an increase of the formation of the ELAVL1/HuR
protein- SQSTM1/p62 mRNA complex. Therefore the binding of
ELAVL1/HuR to a low affinity mRNA sequence, such as
SQSTM1/p62, can best be explained by an alteration in the
stoichiometric parameters regulating the mass action law. The
increase of ELAVL1/HuR at both mRNA and protein levels in
MG-132-treated cells suggests that the ELAVL1/HuR protein up-
regulation may be due not only to proteasome inhibition but also
to an effect on new ELAVL1/HuR protein synthesis.
In confirmation of the specific involvement of ELAVL1/HuR
protein in SQSTM1/p62 post-transcriptional expression regula-
tion, we observed that the MG-132-induced increase of
SQSTM1/p62 protein was blunted in ELAVL1/HuR silenced
RPE cells. Accordingly, we found that, in ELAVL1/HuR-silenced
cells, the MG-132 exposure leads to an up-regulation of SQSTM1/
p62 mRNA expression in a less extent than in MG-132-treated
control cells, suggesting that physiologically the MG-132-mediated
SQSTM1/p62 increase occurs at both transcriptional and post-
transcriptional level, the latter one via ELAVL1/HuR protein.
These findings are particularly striking since post-transcriptional
mechanisms are emerging as fundamental, precise regulators of
gene expression in many stress-related conditions [44,45].
Moreover, our results are in line with a report showing that, in
human fibroblasts, MG-132 induces ELAVL1/HuR export to the
cytoplasm, where it promotes the stabilization/translation of target
mRNAs [46].
For the first time we show that, when co-treated with
proteasome inhibitor MG-132, AICAR triggered autophagy in
ARPE-19 cells, as indicated by the increase of both LC3 lipidation
and autophagosome vesicles formation. As well as for AICAR, we
found that also starvation alone cannot induce autophagy in
ARPE-19 cells: indeed, both AICAR and starvation require the
presence of MG-132 to trigger autophagic process. Notably,
LC3II increase was detectable, respectively, after 0,5 h treatment
with AICAR+MG-132, and 3 h treatment with starvation+MG-
132, suggesting a different time course for autophagy activation by
the two co-stimuli.
In ARPE-19 cells the MG-132–mediated increase of
SQSTM1/p62 protein levels was robustly counteracted by the
autophagy inducer AICAR. In contrast to SQSTM1/p62, the
MG-132-triggered accumulation of ELAVL1/HuR protein was
not affected by AICAR treatment, pointing to different proteolytic
mechanisms between SQSTM1/p62 and ELAVL1/HuR: one
being decreased in autophagy and the other involving the
proteasomal pathway, respectively. Accordingly, a previous
observation in another human cellular model reported that HuR
could undergo proteasome mediated proteolysis [47].
Moreover, by using pDendra2-hLC3 (MAP1LC3A/LC3) and
pDendra2-hp62 (SQSTM1/p62) plasmids, with which the posi-
tion of the protein in the cell can be detected from a desired time
point, we analyzed protein trafficking in cells [48], showing that
both molecules involved in autophagy simultaneously disappeared
via induction of autophagy in response to MG-132 and AICAR
co-treatment. As far as we are aware, this is the first time that the
binding of SQSTM1/p62 protein to perinuclear aggregates has
been revealed as an irreversible process. We recently documented
that when SQSTM1/p62 mRNA was silenced, ubiquitin localiza-
tion in perinuclear aggregates and autophagosome formation were
disturbed in ARPE-19 cells; here we show that AICAR treatment
alone does not decrease SQSTM1/p62 protein levels, indicating
that selective SQSTM1/p62 degradation in autophagy is favoured
when ubiquitinated aggregates are present, as previously docu-
mented [49,21]. It is noteworthy, that AICAR significantly
decreased protein aggregates and improved survival in MG-132-
treated RPE cells, providing clear evidence for an AICAR-
mediated protective effect in this stressful condition. AICAR is a
well-known autophagy inducer which acts via AMPK signalling,
although it may well have other effects in different experimental
models [50–55].
Interestingly, it has been demonstrated that in human AMD
donor samples both accumulations of autophagic markers and
decreased lysosomal activity can be observed [56]. Furthermore,
an effective autophagic clearance system has been recently
documented in human RPE cells [21,57–59]. During aging,
lipofuscin accumulates in lysosomes – this is evidence for a
declining cellular capability to degrade proteins [60]. In addition,
lipofuscin promotes the misfolding of intracellular proteins, which
exerts an additional oxidative stress in the RPE cells [61,62].
As recently suggested by our group [21] and here confirmed in
detail, the SQSTM1/p62 clearance via autophagy can be
prevented by the lysosome inhibitor bafilomycin. Under bafilo-
mycin treatment, an intense autophagosome formation, in parallel
with SQSTM1/p62 accumulation, can be observed, further
confirming SQSTM1/p62 as agood marker for impaired autoph-
agy.
Our human AMD samples here studied show a significant
elevation of SQSTM1/p62 protein levels in the macula, strongly
indicating that SQSTM1/p62 accumulation may be an index of
impaired autophagy. In addition, most of the drusen of AMD
patients were strongly ubiquitin positive, but staining for
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SQSTM1/p62 was observed only intracellularly. This might
imply that SQSTM1/p62 is mostly degraded by the autophagic
pathway and, unlike ubiquitin, SQSTM1/p62 is not exocytosed to
the extracellular space of the RPE cells [6,63,56]. Recently
published papers have reported that ubiquitin and SQSTM1/p62
are strongly co-localized in the perinuclear aggregates [19,21], but
here we could detect only ubiquitin in the extracellular drusen of
AMD samples. ELAVL1/HuR protein level staining in human
dry AMD macula was rather reduced, although not significantly.
Since ELAVL1/HuR is degraded in proteasomes, our findings
provide evidence that proteasomes are active in these AMD cases,
even though proteasomal activity may decrease during aging in
the RPE cells [62,64,65]. As a confirmation of our hypothesis, the
foveomacular areas from control no-AMD patients showed weak
staining for SQSTM1/p62, ELAVL1/HuR, ubiquitin proteins,
comparable to those observed in perimacular and peripheral
retina of AMD patients.
Besides many recent advances in the understanding of
autophagy mechanisms, it is now widely accepted that dysfunc-
tions in these processes have a key role in many neurodegenerative
diseases, including AMD. Moreover, autophagy is increasingly
emerging as a novel target of therapies aimed to counteract
protein aggregation and improve cell viability; within this context,
preservation of autophagy may protect RPE cell from degener-
ation and thus represents a potential tool to slow or even prevent
the development of AMD [66].
Supporting Information
Figure S1 MG-132 induces ELAVL1/HUR and SQSTM1/
p62 accumulation. A densitometric analysis of SQSTM1/p62 (A)
and ELAVL1/HuR (B) proteins in the nuclear/perinuclear
compartment (left panels) and in the cytoplasm (right panels) of
ARPE-19 cells after exposure to MG-132 (5 mM) for 24 h. Control
cells were exposed to solvent (DMSO). a-tubulin was used as a
loading control. Results are expressed as means 6 S.E.M.;
*p,0.05, **p,0.01, ***p,0.001, control vs. treated cells,
Student’s t test; n = 7.
(TIF)
Figure S2 The 24 h MG-132-mediated upregulation of
SQSTM1/p62 mRNA expression is counteracted by the
ELAVL1/HuR silencing. Determination of ELAVL1/HuR (A)
and SQSTM1/p62 (B) mRNA levels by real-time qPCR in the total
homogenates of control (CTR), MG-132-treated cells (MG-132),
and MG-132-treated ELAVL1/HuR silenced ARPE-19 cells
(ELAVL1/HuR-siRNA+MG-132). ELAVL1/HuR and SQSTM1/
p62 mRNA levels in control cells were taken as 100% in (A) and
(B), respectively. Control cells were exposed to solvent (DMSO).
The values obtained from total cellular mRNA have been
normalized to the level of RPL6 mRNA and expressed as mean
6 S.E.M. ***p,0.001 control vs. treated cells; ¤¤¤p,0.001
ELAVL1/HuR-siRNA+MG-132 vs. MG-132; Tukey’s multiple
comparison test; n = 3.
(TIF)
Figure S3 AICAR is well-tolerated and prevents cell death in
MG-132 long-exposed ARPE-19 cells. (A): Maximum release of
lactate dehydrogenase (LDH) enzyme in ARPE-19 cells treated
with MG-132 5 mM and/or AICAR 2 mM for 24 h. Celastrol (10
mM) treatment is reported as a positive control since it induces
maximum LDH release. Results are presented as mean optical
density (OD) 6 S.E.M. (n = 6, Mann-Whitney). (B): Cell death of
ARPE-19 cells treated with MG-132 5 mM and/or AICAR 2 mM
up to 72 h. Percent cell death of ARPE-19 cells (early apoptotic or
annexin V-FITC+ cells 2black bar- and late apoptotic or annexin
V-FITC/propidium iodide+ cells 2white bar) under different
treatments. Data shown are mean+S.D. For late apoptosis
***p,0.001 Student’s t test; n = 3. For early apoptosis
¤¤p,0.01, ¤¤¤p,0.001 Student’s t test; n = 3.
(TIF)
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